A detailed history of Tri Locum Partners LP transactions in Merus N.V. stock. As of the latest transaction made, Tri Locum Partners LP holds 192,157 shares of MRUS stock, worth $8.15 Million. This represents 2.56% of its overall portfolio holdings.

Number of Shares
192,157
Previous 335,514 42.73%
Holding current value
$8.15 Million
Previous $19.9 Million 51.64%
% of portfolio
2.56%
Previous 5.13%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$47.19 - $58.84 $6.77 Million - $8.44 Million
-143,357 Reduced 42.73%
192,157 $9.6 Million
Q2 2024

Aug 14, 2024

BUY
$39.81 - $60.2 $1.96 Million - $2.96 Million
49,192 Added 17.18%
335,514 $19.9 Million
Q1 2024

May 15, 2024

BUY
$28.03 - $51.82 $8.03 Million - $14.8 Million
286,322 New
286,322 $12.9 Million
Q2 2023

Aug 14, 2023

BUY
$18.33 - $27.18 $1.86 Million - $2.76 Million
101,691 New
101,691 $2.68 Million

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $1.95B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Tri Locum Partners LP Portfolio

Follow Tri Locum Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tri Locum Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Tri Locum Partners LP with notifications on news.